Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) and Wellgistics Health (NASDAQ:WGRX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a summary of current recommendations and price targets for Indaptus Therapeutics and Wellgistics Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Indaptus Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Wellgistics Health | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Indaptus Therapeutics and Wellgistics Health”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Indaptus Therapeutics | N/A | N/A | -$20.85 million | ($15.40) | -0.14 |
| Wellgistics Health | $23.34 million | 0.47 | -$101.28 million | ($44.50) | -0.10 |
Indaptus Therapeutics has higher earnings, but lower revenue than Wellgistics Health. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Indaptus Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Wellgistics Health has a beta of -1.45, suggesting that its stock price is 245% less volatile than the S&P 500.
Institutional and Insider Ownership
7.1% of Indaptus Therapeutics shares are owned by institutional investors. 23.6% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 27.0% of Wellgistics Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Indaptus Therapeutics and Wellgistics Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Indaptus Therapeutics | N/A | -1,030.07% | -299.69% |
| Wellgistics Health | -545.69% | -1,617.25% | -145.69% |
Summary
Indaptus Therapeutics beats Wellgistics Health on 6 of the 10 factors compared between the two stocks.
About Indaptus Therapeutics
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
About Wellgistics Health
Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. In January 2023 and May 2023, Wellgistics Health entered into separate definitive agreements with the owners of Wood Sage and Wellgistics LLC, respectively, whereby Wellgistics Health would acquire all of the respective outstanding membership interests of Wood Sage and Wellgistics LLC. In June 2024, Wellgistics Health and Wood Sage entered into an amended and revised definitive agreement and closed on the Wood Sage Acquisition, thereby making Wood Sage a wholly owned subsidiary of Wellgistics Health. In connection with the Wood Sage Acquisition, Wellgistics Health acquired Wood Sage’s two operating subsidiaries, APS—a pharmaceutical technology hub—and CSP—a retail community specialty pharmacy. On August 30, 2024, Wellgistics Health closed on the Wellgistics Acquisition, thereby making Wellgistics LLC—a company focused on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies meant to improve market access to and patient outcomes regarding the medications—a wholly owned subsidiary of Wellgistics Health. As such, Wellgistics Health currently exists as a holding company with Wood Sage as a directly held intermediate holding company subsidiary, APS and CSP as indirect operating subsidiaries, and Wellgistics LLC as a direct operating subsidiary. On October 4, 2024, the Company changed its corporate name to “Wellgistics Health, Inc.” by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. Despite that Wellgistics Health only recently closed the Wood Sage Acquisition and the Wellgistics Acquisition during 2024, the three companies have shared common office space, comarketed solutions to the marketplace, and leveraged financial and back-office support prior to June 2024. As such, Wellgistics Health’s management believes that its close business relationships have and will continue to limit the need for post-closing integration. The mailing address of our principal executive office is 3000 Bayport Drive, Suite 950 Tampa, FL.
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
